ChemotherapyFDA-approvedSecond-line
Lonsurf
Generic name: trifluridine/tipiracil
How it works
Inhibits DNA synthesis in cancer cells, causing cell death. Also, inhibits the formation of new blood vessels that feed the tumor.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Lonsurf improved overall survival and progression-free survival in patients with metastatic colorectal cancer who have failed prior chemotherapy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Older Colorectal Cancer Patients' Response to Trifluridine/Tipiracil with or without Bevacizumab | Colorectal Cancer | observational | Median OS was longer in the combination therapy group (18.3 vs. 8.3 months). | Source → |
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Trifluridine/Tipiracil Treatment in Metastatic Colorectal Cancer | Colorectal Cancer | observational | Median overall survival was 7.59 months. | Source → |
| Trifluridine/Tipiracil Combinations Show Promise in Advanced Colorectal Cancer | Colorectal Cancer | review | Median overall survival ranged 8.6-14.4 months and median progression-free survival 3.7-6.8 months with FTD/TPI plus bevacizumab in refractory mCRC. | Source → |
| Real-World Comparison of Cancer Treatments Shows Similar Outcomes | Colorectal Cancer | observational | Median OS for the TAS-102 alone or prior regorafenib group was 6.66 months compared with 6.30 months for regorafenib alone or prior to TAS-102. | Source → |
| Elderly Patients Benefit from Trifluridine/Tipiracil for Colorectal Cancer | Colorectal Cancer | observational | In elderly patients with mCRC, FTD/TPI treatment was effective for prolonging survival. | Source → |
| Trifluridine/Tipiracil Shows Promise for Metastatic Colorectal Cancer Patients | Colorectal Cancer | observational | The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. | Source → |
| Italian Study Confirms Safety and Efficacy of Trifluridine/Tipiracil in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | The median progression-free survival was reached at 3.0 months, with a disease control rate of 28.6%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.